Health Condition 1: null- Female epileptic patients
Conditions
Interventions
Intervention1: Anti-Epileptic Drugs: Phenytoin-300mg/day
Phenobarbitone-150-200mg/day
Carbamazepine-1g/day
Valproic acid-1-3g/day
Levetriacetam-0.5-3.0g/day
Control Intervention1: NIL: NIL
Sponsors
KG Hospital and Postgraduate Research Institute
Eligibility
Inclusion criteria
Inclusion criteria: •Female patients diagnosed with epilepsy and under anti-epileptic drug therapy for at least a period of two years •The patient aged 15 to 45 •Patients with same characteristics both physically as well as clinically •Both in-patients and out-patients of department of Neurology. •The patients who are keeping up their regular follow-up appointments. •The patient who are willing to give informed content.
Exclusion criteria
Exclusion criteria: •Pre-pubertic girls and postmenopausal women. •Patients with conditions known to affect bone metabolism such as hepatic or renal disorders, hypothyroidism, or malabsorption. •Patients with a history of intake of pharmacologic amounts of medications that can affect bone turn over (e.g., Vitamin A, anabolic steroids, bisphosphonates, glucocorticoids, thiazides, calcitonin) •Patients from pediatrics, pregnant women, gynecological patients with hormone imbalance and emergency •Psychiatric patients •Patients not coming for regular follow up •Patients who are not willing to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improved Bone mineral densityTimepoint: 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Decreased Fracture RiskTimepoint: 1 year | — |
Countries
India
Contacts
Public ContactSabna M
RVS College Of Pharmaceutical Sciences
Outcome results
None listed